Streetbeat News

Revenues

ADTN

Adtran Holdings (NASDAQ:ADTN) has been analyzed by 4 analysts in the last three months, showing a mix of bullish and indifferent ratings. The average 12-month price target is $7.88, down 7.29% from the previous $8.50. Analyst actions include maintaining and lowering ratings, with price targets ranging from $7.50 to $8.00. Adtran Holdings, a provider of networking and communications solutions, faces challenges with a -37.06% revenue decline and below-average profitability metrics. Despite this, its debt-to-equity ratio suggests a sound financial structure.

Portfolio Pulse from Benzinga Insights

May 08, 2024 | 8:01 pm

GEO

Six analysts have recently rated GEO Group (NYSE:GEO), all somewhat bullish, with a 12-month price target average of $16.83, a slight decline from the previous target. Analyst Jay McCanless from Wedbush has made multiple adjustments to his price targets and ratings, maintaining an 'Outperform' stance. GEO Group, specializing in detention facilities and community reentry centers, faces financial challenges with a -2.0% revenue growth, a net margin of 3.44%, and a high debt-to-equity ratio of 1.46.

Portfolio Pulse from Benzinga Insights

May 08, 2024 | 8:01 pm

RRR

Analyst ratings for Red Rock Resorts (NASDAQ:RRR) show a mix of bullish to bearish sentiments, with recent updates indicating a positive shift in price targets. The average 12-month price target has risen to $61.92, reflecting a 3.06% increase. Analyst actions include both upgrades and downgrades, with price targets ranging from $51.00 to $69.00. Red Rock Resorts has demonstrated solid revenue growth and profitability, but faces challenges with a high debt-to-equity ratio.

Portfolio Pulse from Benzinga Insights

May 08, 2024 | 8:01 pm

PR

Permian Resources (NYSE:PR) has received diverse analyst ratings over the last three months, with 20 analysts offering perspectives ranging from bullish to bearish. The average 12-month price target for PR is $19.85, reflecting a 6.95% increase from the previous target of $18.56. Analyst actions include rating adjustments and changes in price targets, indicating a generally positive outlook on PR's performance. The company's financial indicators such as revenue growth, net margin, ROE, and ROA are impressive, outperforming industry averages, although it faces challenges with a high debt-to-equity ratio.

Portfolio Pulse from Benzinga Insights

May 08, 2024 | 8:00 pm

ITCI

Intra-Cellular Therapies (NASDAQ:ITCI) has been the subject of diverse analyst ratings over the last three months, with a total of 18 analysts offering opinions ranging from bullish to bearish. The average 12-month price target for ITCI has been raised to $91.94, marking an 11.44% increase from the previous average of $82.50. Analysts from firms including Needham, Cantor Fitzgerald, Canaccord Genuity, Mizuho, Goldman Sachs, B of A Securities, TD Cowen, Baird, and RBC Capital have updated their ratings and price targets, reflecting a generally positive outlook on the company's performance. Intra-Cellular Therapies, a biopharmaceutical company focusing on central nervous system diseases, has shown a notable revenue growth rate of 50.41% over the past three months, despite challenges in net margin, ROE, and ROA.

Portfolio Pulse from Benzinga Insights

May 08, 2024 | 8:00 pm

WMS

Advanced Drainage Systems (NYSE:WMS) has been evaluated by 4 analysts over the last three months, showing a shift towards a more bullish stance. The average 12-month price target for WMS is now $184.25, marking a 17.6% increase from the previous target of $156.67. Analysts from Northcoast Research, Oppenheimer, Keybanc, and Stephens & Co. have adjusted their ratings and price targets, reflecting optimism about the company's performance. Despite its market capitalization being below the industry average, Advanced Drainage Systems has shown notable revenue growth and exceptional net margin and ROE, although it faces challenges in debt management.

Portfolio Pulse from Benzinga Insights

May 08, 2024 | 8:00 pm

WAL

Analysts have provided diverse opinions on Western Alliance (NYSE:WAL) over the last three months, with ratings ranging from bullish to bearish. The average 12-month price target is now $78.62, down from $81.67. Recent actions by analysts include maintaining, lowering, and raising ratings and price targets, reflecting changes in market conditions and company performance. Western Alliance Bancorporation, based in Las Vegas, operates regional banks and has shown significant revenue growth and net margin, but faces challenges in ROA and debt management.

Portfolio Pulse from Benzinga Insights

May 08, 2024 | 7:01 pm

FWRG

First Watch Restaurant Gr (NASDAQ:FWRG) has been analyzed by 8 analysts, showing a mix of ratings from bullish to indifferent. The average 12-month price target is now $26.75, up 14.32% from the previous $23.40. Recent actions include adjustments to ratings and price targets by analysts from Barclays, TD Cowen, Stifel, and Citigroup. The company, known for its daytime restaurant concept, has shown a revenue growth of 31.7% as of December 31, 2023, but struggles with profitability and efficiency metrics compared to industry averages.

Portfolio Pulse from Benzinga Insights

May 08, 2024 | 7:01 pm

ML

Analysts have recently updated their ratings and price targets for MoneyLion (NYSE:ML), showing a mix of bullish sentiments. The average 12-month price target has been raised to $101.83, marking a 19.8% increase from the previous target of $85.00. This positive adjustment reflects analysts' growing confidence in MoneyLion's financial performance and market position, as evidenced by its revenue growth rate of 18.98% and its strategic positioning in the financial sector despite challenges in profitability and asset utilization.

Portfolio Pulse from Benzinga Insights

May 08, 2024 | 7:01 pm

PRA

ProAssurance (NYSE:PRA) received mixed analyst ratings in the latest quarter with 5 analysts offering views that ranged from somewhat bullish to indifferent. The average 12-month price target for PRA is now $17.8, marking a 4.71% increase from the previous target of $17.00. Analyst actions included both raises and lowers in ratings and price targets, reflecting adjustments to market conditions and company performance. ProAssurance, a holding company for various insurance subsidiaries, has shown a revenue growth rate of 2.9% as of March 31, 2024, but trails behind industry averages in ROE and ROA, despite a strong net margin of 1.64% and a low debt-to-equity ratio.

Portfolio Pulse from Benzinga Insights

May 08, 2024 | 7:00 pm